The company's total revenues in the quarter ended Dec. 31, 2005, increased to $1.34 billion from $1.21 billion in the year-ago period. Revenues from the Bio-Analytical Measurement segment climbed 5 percent to $373 million from $354 million, while orders rose to $378 million in the quarter from $356 million a year earlier.
Agilent's research and development spending in the first quarter rose to $189 million from $175 million in the year-ago quarter.
The company's first-quarter adjusted net income jumped to $154 million, or $.32 per share, from $71 million, or $.15 per share, the year before. These numbrs excluded charges related to the planned spin off of Agilent's Semiconductor Test Solutions unit and the reduction in infrastructure costs, as well as related non-cash stock compensation expenses.
As of Jan. 31, Agilent had cash and cash equivalents totaling $2.7 billion.